Michael Bornemann, MD
Endocrinology · Honolulu, HINPI 1184622920
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 687 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 687 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$1K
- Amgen$1K
- Radius Health, Inc.$951
- plus $5K from 19 others
What the payments were for
- Food & beverage$13,01596%
- Education$4333%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 157 | $2,615 |
| Lilly USA, LLC | 87 | $1,620 |
| Sanofi-aventis U.S. LLC | 75 | $1,402 |
| AstraZeneca(2 entities) | 61 | $1,260 |
| Amgen(2 entities) | 46 | $1,019 |
| Radius Health, Inc. | 40 | $951 |
| Boehringer Ingelheim | 31 | $799 |
| Dexcom, Inc. | 36 | $709 |
| Bayer | 31 | $627 |
| Insulet Corporation | 27 | $598 |
| Mannkind Corporation | 22 | $449 |
| Merck | 17 | $337 |
| Johnson & Johnson | 18 | $239 |
| Abbott | 12 | $205 |
| Pfizer | 5 | $148 |
| Corcept Therapeutics | 6 | $141 |
| Medtronic(2 entities) | 5 | $128 |
| Chiesi USA, Inc. | 2 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Amryt Pharma Holdings Ltd | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 258 | $472,160 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 210 | $226,376 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 153 | $216,609 |
| JardianceEmpagliflozin | 116 | $170,172 |
| TrulicityDulaglutide | 92 | $150,629 |
| TymlosAbaloparatide | 33 | $97,523 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 67 | $82,054 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $69,943 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 64 | $66,484 |
| ProliaDenosumab | 30 | $53,164 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $43,450 |
| SynjardyEmpagliflozin/Metformin Hcl | 29 | $43,071 |
| Xigduo XrDapaglifloz Propaned/Metformin | 36 | $38,550 |
| RybelsusSemaglutide | 15 | $38,235 |
| FarxigaDapagliflozin Propanediol | 24 | $34,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,615 | $515,643291 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $799 | $429,852298 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,620 | $184,097116 claims |
| MerckJanumet Xr, Janumet, Januvia | $337 | $171,441122 claims |
| Radius Health, Inc.Tymlos | $951 | $97,52333 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,402 | $66,48464 claims |
| AmgenProlia | $1,019 | $53,16430 claims |
| Johnson & JohnsonInvokana, Invokamet | $239 | $50,41631 claims |
| AstraZenecaFarxiga | $1,260 | $34,51724 claims |
| Mannkind CorporationAfrezza | $449 | $28,26723 claims |
| BayerKerendia | $627 | $22,82812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other endocrinology in Honolulu
- David Fitz-PatrickHonolulu$502
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.